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Abstract
Background: Survivors of a cardiac arrest often have persistent cardiovascular derangements following
cardiopulmonary resuscitation including decreased cardiac output, arrhythmias and morphological myocardial
damage. These cardiovascular derangements may lead to an increased susceptibility towards the external and
internal environment of the cardiovascular system as compared to the healthy situation.
Methods: Here we tested the hypothesis that the cardiovascular system in healthy rats and rats resuscitated from
a cardiac arrest may be differentially affected by a transient receptor potential vanilloid type 1 agonist, by
continuous intravenous infusion of dihydrocapsaicin (DHC).
Results: Compared to baseline, infusion of DHC caused an initial increase in mean arterial blood pressure in both
healthy and resuscitated rats of 25% and 10%, respectively. Also, we observed an initial response of tachycardia in
both healthy and resuscitated rats of 30% and 20%, respectively. Then, at high levels of DHC infusion (> 2.0 mg/
kg/hr) we observed two single episodes of transient bradycardia and hypotension in 33% of the healthy rats,
which was consistent with a TRPV1 agonist induced Bezold-Jarisch reflex. In contrast, in resuscitated rats we
observed multiple episodes of bradycardia/hypotension in 100% of the rats and at a dose of DHC of 0.65 mg/kg/
hr. Notably, this DHC effect could be completely blocked in the resuscitated rats by pre-treatment with atropine, a
muscarinic acetylcholine antagonist.
Conclusions: Our results indicate that the susceptibility of the rats towards TRPV1 agonist induced Bezold-Jarisch
reflex is increased in those resuscitated from cardiac arrest compared to the healthy situation.
Background
The transient receptor potential vanilloid type 1
(TRPV1) is a member of the mammalian transient
receptor potential family of ion channels [1] and was
cloned in 1997 [2]. TRPV1 is a non-selective cation
channel with a preference for calcium, which can be
directly activated by noxious heat (> 43°C), extracellular
acidification, as well as a large heterogeneous group of
natural compounds such as dihydrocapsaicin (DHC)
from chili pepper [3,4]. The TRPV1 receptor is widely
expressed in the human body [5,6] particularly in “port-
of-entry” tissues, the central nervous system (CNS), and
in the peripheral nervous system in primary small to
medium diameter sensory neurons such as dorsal root,
trigeminal, and nodose ganglia that give rise to C-fibers
and Aδ-fibers [2,7]. The TRPV1 receptor is involved in
several biological systems including thermosensation
and regulation [8,9] and the sensation of pain [10-12].
Also, in the lung the TRPV1 receptors play an impor-
tant role in the regulation of respiratory functions [13].
Thus, via stimulation of lung TRPV1 receptors by
inhaled irritants may elucidate airway reflexes including
cough and bronchoconstriction [13].
We have demonstrated the feasibility of using TRPV1
agonist for obtaining drug-induced mild therapeutic
hypothermia in healthy animals (accompanying manu-
script). Accordingly this pharmacological approach for
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obtaining therapeutic hypothermia may prove beneficial
in patients resuscitated from a cardiac arrest. On the
other hand, a transient receptor potential vanilloid type
1 agonist may differentially affect the cardiovascular sys-
tem in health and in the compromised situation as fol-
lowing cardiac arrest and cardiopulmunary resuscitation.
The heart is richly innervated by sensory and vagal
nerve endings. These nerves transduce chemical and
mechanical changes from the heart to the brain. Inter-
estingly, sensory nerve endings supplying the heart
express TRPV1 [14]. However, the role of TRPV1 recep-
tors in the cardiovascular system is currently not under-
stood and the reported data are equivocal. Thus, it has
been shown that administration of capsaicin caused bra-
dycardia and hypotension in anaesthetized dogs or rab-
bits [15,16], whereas in studies in anaesthetized dogs
using intravenous infusion of a chemically pure capsai-
cin a transient increase in heart rate and blood pressure
was demonstrated [17]. Moreover, in anaesthetized gui-
nea pigs it has been observed that capsaicin evokes a
biphasic change of heart rate with a prominent brady-
cardia as an initial component [18] or a triphasic blood
pressure response in anesthetized rat following intrave-
nous administration of the TRPV1 agonist anandamide
[19]. Interestingly, in TRPV1 receptor knock-out mice
injection of capsaicin caused no changes in arterial
blood pressure in contrast to the clear response in con-
trol mice expressing TRPV1 [20].
Activation of the peripheral termini of TRPV1 receptors
causes the release of various pro-inflammatory neuropep-
tides such as substance P (SP), neurokinin A (NKA), and
calcitonin gene-related peptide (CGRP) [4,21], which in
turn affect the cardiovascular system. The primary phar-
macological action of SP in the isolated spontaneously
beating heart is to decrease heart rate and relax coronary
resistance vessels [22-24]. The effects of SP on the cardiac
system can be blocked by atropine, a competitive antago-
nist of the muscarinic acetylcholine receptor, showing that
it is mediated by the cholinergic nerves [23,25]. On the
other hand, the effect of NKA, which is co-stored with SP
in capsaicin-sensitive nerves also causes bradycardia, but
via both cholinergic and non-cholinergic nerves [18]. In
contrast to SP and NKA, GCRP causes tachycardia in iso-
lated guinea pig heart preparations via stimulation of the
GCRP receptor [26,27].
In the present study, our goals were to investigate the
effect of continuous intravenous infusion of the TRPV1
agonist DHC on the cardiovascular system in conscious
rats, and in a model of a compromised cardiovascular
system, i.e. the anesthetized rat following cardiac arrest
and cardiopulmonary resuscitation. The TRPV1 agonist
DHC and infusion paradigm was selected based on
feasibility studies of the ability to induce mild therapeu-




Cardiovascular studies in healthy rats were performed at
Covance Inc. (Greenfield, IN, USA) and initiated in
6 male Sprague-Dawley CD/IGS rats (Charles River,
Portage, Michigan, USA). Rats were housed under con-
trolled temperature (22 ± 5°C) and humidity conditions
(20 - 80%) at a 12 hour normal dark-light cycle (lights
on at 06.00 AM) with free access to water and chow
(Rodent 2014, Harlan Teklad Global Diets, Indianapolis,
IN, USA). The procedures in this study were designed
to avoid or minimize discomfort, distress, and pain to
animals and in compliance with the U.S. Department of
Agriculture’s (USDA) Animal Welfare Act (9 CFR Parts
1, 2, and 3), the Guide for the Care and Use of Labora-
tory Animals (Institute of Laboratory Animal Resources,
National Academy Press, Washington, D.C., 1996), and
the National Institutes of Health, Office of Laboratory
Animal Welfare.
Experimental
At least five days prior to infusion the animals were
implanted with a DSI Physiotel® Multiplus C50-PXT
transmitter (Data Sciences International, St Paul, MN,
USA) and a 6-inch beaded polyurethane intravenous
catheter (Strategic Applications Inc., Libertyville, IL,
USA) set in the jugular vein using aseptic surgical tech-
nique. The animals received buprenorphine hydrochlor-
ide (0.1 mg/kg, Reckitt Benckiser Pharmaceuticals Inc.,
Richmond, VA, USA) prior to surgery and ketoprofen
(3 mg/kg, Fort Dodge Animal Health, Fort Dodge, IA,
USA) following surgery, and were anesthetized with iso-
flurane (Abbott Laboratories, Abbott Park, IL, USA)
throughout the surgical procedure. The DSI system was
connected to a data acquisition and analysis system
(PONEMAH, Data Sciences International, St. Paul, MN,
USA) and enabled to measure systemic arterial pressure
and blood temperature. The arterial pressure signal was
used to derive systolic, diastolic, and mean arterial pres-
sure as well as heart and respiratory rate. Although data
was continuously acquired, derived parameters were col-
lapsed into mean values computed over repetitive log-
ging periods. Data was recorded from 2 hours before
starting the infusion until approximately 6.00 AM the
following day. A freshly prepared solution of dihydro-
capsaicin (0.8 mg/ml, Lot 63908, Clauson Kaas, Farum,
Denmark) dissolved in 2% tween 80 (Spectrum Chemi-
cals and Laboratory Products, Gardena, CA, USA) and
saline and vehicle control was prepared and sterile
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filtered before on-set of the infusion. Following a 2 hour
settling period and using a KD scientific pump (KD
Scientific Inc, Holliston, MA, USA), vehicle control was
infused for 1 hour at a flow rate of 3 ml/kg/hr. Next,
DHC was infused in 5 steps each lasting 1 hour at the
doses of 1.0, 2.0, 2.2, 2.4, and 3.0 mg/kg/hr corresponding
to a flow rate of 1.25, 2.5, 2.75, 3.0, and 3.75 ml/kg/hr.
Following the termination of the infusion animals were
euthanized by CO2 inhalation followed by cervical
dislocation.
Cardiac arrested and resuscitated rats
Animals
Studies in resuscitated rats were performed at the Weil
Institute of Critical Care (Rancho Mirage, CA, USA) in
male Sprague-Dawley rats (Harlan Laboratories Inc.,
station #237, San Diego, CA, USA) aged 6-8 months
and weighing 496-523 grams. Animals were housed in
groups of 2-3 per cage in a temperature (23 ± 3°C) and
humidity (30 - 40%) controlled room and a 12 hour
light-dark cycle (lights on at 06.00 AM). Rat diet
(NEWCO Distributors, Inc, Rancho Cucamonga, CA,
USA) and water were available ad libitum except that
food was deprived 12 hours prior to surgery. All animals
received humane care in compliance with the Guide for
the Care and Use of Laboratory Animals prepared by
the Institute of Laboratory Animal Resources and pub-
lished by the National Institutes of Health (National
Institutes of Health publication 0-309-05337-3, Revised
1996). The protocol was approved by the Institutional
Animal Care and Use Committee of the Weil Institute
of Critical Care Medicine. The Weil Institute of Critical
Care Medicine Laboratories is fully accredited by the
Association for Assessment and Accreditation of
Laboratory Animal Care International.
Preparation and surgery
The animals were anesthetized by an intraperitoneal
injection of pentobarbital (45 mg/kg) and additional
doses (10 mg/kg) were administrated as required to
maintain anesthesia. Antibiotic treatment with cefazolin
(250 mg, Moore Medical Corp., New Britain, CT, USA)
was administered by intramuscular injection prior to the
start of surgery, and a second dose at the end of the
experiment. The trachea was orally intubated with a 14
G cannula mounted on a blunt needle with a 145°
angled tip (Abbocath-T, Abbott Hospital, North Chi-
cago, IL, USA) as previously described [28]. During sur-
gery animals were spontaneously breathing air and the
temperature of the animal was maintained at 37°C ±
0.2°C with the aid of a heating lamp. Blood temperature
was measured with a thermocouple microprobe 10 cm
in length and 0.5 mm in diameter (9030-12-D-34,
Columbus Instruments, Columbus, OH, USA) that was
inserted into the right femoral artery and advanced to
the distal ascending aorta. A polyethylene catheter
(PE-50; Becton-Dickinson, Franklin Lakes, NJ, USA) was
advanced into the descending aorta from the surgically
exposed left femoral artery for measurement of arterial
blood pressure. Electrocardiography (ECG) was continu-
ously monitored by a conventional lead II and end-tidal
CO2 was continuously monitored with a side-stream
infrared CO2 analyzer (End-Til IL 200; Instrument
Laboratory, Lexington, MA, USA). A polyethylene
catheter (PE-50; Becton-Dickinson, Franklin Lakes, NJ,
USA) was advanced from the left femoral vein into the
inferior cava vein for subsequent infusion of compound.
All catheters were flushed intermittently with hepari-
nized saline (2.5 IU/ml of BSA, Western Medical
Supple, Arcadia, CA, USA).
Cardiac arrest procedure
The cardiac arrest and resuscitation procedure was per-
formed as previously described [29,30]. Briefly, fifteen
minutes prior to inducing ventricular fibrillation (VF),
baseline measurements were obtained and mechanical
ventilation was initiated with an inspired O2 fraction
(FiO2) of 0.21. Ventricular fibrillation was then induced
through a guide wire (model C-PMS-301J, Cook Critical
Care, Bloomington, IN, USA) advanced from the right
jugular vein into the right ventricle. A progressive
increase in 60 Hz current to a maximum of 4 mA was
delivered to the right ventricular endocardium and main-
tained for 3 minutes to prevent spontaneous defibrilla-
tion. Mechanical ventilation was stopped at the onset of
cardiac arrest. After 6 minutes of untreated VF, cardio-
pulmonary resuscitation (CPR) including pre-cordial
chest compressions and mechanical ventilation with a
FiO2 of 1.0 was initiated. Chest compressions were per-
formed with the aid of a pneumatically driven mechanical
chest compressor at a rate of 200 per minute and
synchronized to provide a compression-to-ventilation
ratio of 2-to-1 with equal compression-relaxation. The
depth of compressions was initially adjusted to maintain
a coronary perfusion pressure above 23 mmHg and with
end-tidal CO2 above 11 mmHg. After 6 minutes of CPR,
resuscitation was attempted with up to 3 two-joule
counter shocks. Return of spontaneous circulation
(ROSC) was defined as the return of supraventricular
rhythm with a mean aortic pressure above 50 mmHg
for at least five minutes. If ROSC was not achieved, a
30 second interval of CPR was performed prior to
attempt of a subsequent sequence of up to 3 shocks. The
procedure was repeated for a maximum of 3 cycles. If
ROSC was not achieved the animal was terminated and
excluded from the study.
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Infusion
Following ROSC animals were allowed to stabilize for
30 minutes and stratified into 2 groups (n = 4) receiving
a 6 hour infusion of DHC with or without pre-treatment
with atropine (5 mg/kg, Moore Medical Corp., New
Britain, CT, USA). Atropine was administered as a 4 IV
injections of a 0.4 mg/ml solution every 30 seconds
starting 10 minutes prior to the infusion of
DHC. A freshly prepared solution of dihydrocapsaicin
(0.4 mg/ml, Cat. 92355, Cayman Chemical Company,
AH Diagnostics, Aarhus, Denmark) dissolved in 2%
tween 80 (Sigma-Aldrich, St. Louis, MO, USA) and sal-
ine was prepared and sterile filtered before on-set of the
infusion. Then, at t = 0 hours (corresponding to 30 min-
utes after ROSC) a continuous infusion of DHC was
initiated using a Micro Macro XL pump (Abbott
Laboratories, Chicago, IL, USA) with a flow rate of
0.4 ml/kg from t = 0 to 30 minutes, then 0.8 ml/kg
from t = 30 to 60 minutes, and finally 1.6 ml/kg from
t = 1 to 6 hours corresponding to doses of 0.16, 0.33
and 0.65 mg/kg/hr, respectively. Blood temperature and
arterial blood pressure were recorded 15 minutes before
and then every 15 minutes during the 6 hour infusion.
ECG was recorded throughout the infusion. The ambi-
ent temperature during the infusion was similar to the
conditions during surgery. Following the termination of
the infusion animals were euthanized by intraperitoneal
injection of pentobarbital (150 mg/kg).
Statistical analysis
Data are expressed as mean ± standard error (SE) and
compared by a one-way or two-way ANOVA and
appropriate post-test, unless otherwise stated. P < 0.05
was considered significant. All statistical calculations
were performed using GraphPad Prism version 4.00




Table 1 presents the clinical observations following
treatment with vehicle and DHC. All rats survived to
study termination, and no changes in clinical condition
were observed during infusion with vehicle or during
infusion with DHC at the dose of 1.0 mg/kg/hr. Overt
DHC-related clinical observations involved changes in
activity at doses of 2.0 mg/kg/hr or greater, and piloer-
ection and red pinnae at doses of 2.2 mg/kg/hr or
greater. The changes in activity initially consisted of
apparent restlessness in all animals within 10 minutes
after the start of the 2.0-mg/kg/hr infusion. Other
DHC-related observations consisted of piloerection in
one rat and red pinnae in all animals at the highest
doses of DHC. Vocalization was observed in one rat.
Notably, two rats exhibited motor events characterized
by increased activity and circling in the cage. Simulta-
neously cardiovascular events including bradycardia and
hypotension were seen, as described below. For both
animals, these changes were followed by a period of
recumbence and were associated with apparent stiffness
of the tail. Shallow respiration and apparent muscle tre-
mors of the thorax were also noted for one rat while it
was recumbent. After a short period of 2-3 minutes the
animals returned to normal posture.
Cardiovascular parameters, temperature and respiration
Generally infusion of DHC caused a dose-dependent
increase in mean arterial blood pressure compared to the
vehicle control situation (p < 0.001, Figure 1A). Also, we
observed a dose-related increase in heart rate, with an
increase of approximately 30% compared to vehicle by
the end of the last infusion period (p < 0.001, Figure 1B).
Aortic ejection time (Figure 1C) was increased compared
to vehicle control at all doses of DHC except the final
dose of 3.0 mg/kg/hr. However, simultaneously with the
motor events described above, we observed cardiac
arrhythmias resulting in a marked hypotension and
bradycardia (Figure 2). The length of these periods of
arrhythmia was approximately 2 minutes, after which the
blood pressure and heart rate returned to normal.
Hypothermic properties of TRPV1 agonist including
DHC have been investigated in separate experiments
(accompanying manuscript). Here, body temperature
(Figure 3A) displayed a rapid decrease during the first
DHC infusion period (1.0 mg/kg/hr) and reached the
lowest temperature of 32.7°C, or approximately 4.5°C
below baseline, during the infusion of DHC at 2.0-mg/
kg/hr. Then, during subsequent infusion periods body
temperature increased, but remained below the vehicle
Table 1 Clinical observations in healthy rats
Dose (mg/kg) 0 1.0 2.0 2.2 2.4 3.0
Step 1 2 3 4 5 6
Mortality – – – – – –
Clinical Observations
Apparent restlessness – – All – – –
Increased activity – – Rat 2 – – Rat 1
Circling in cage – – Rat 2 – – Rat 1
Stiff tail – – Rat 2 – – Rat 1
Lateral recumbency – – Rat 2 – – Rat 1
Shallow respiration – – – – – Rat 1
Muscle tremors, thorax – – – – – Rat 1
Vocalizing – – Rat 5 – – –
Piloerection – – – Rat 2 Rat 2 Rat 2
Red pinnae – – – All All All
The table summarizes the clinical observations during the infusion of vehicle
and incremental doses of DHC in conscious healthy rats. If no observations
were made this was noted as “–”, and if an observation was made in all
6 animals this was noted as “All”.
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control situation until the end of infusion. Derived
respiration rate (Figure 3B) were slightly lower during
the 1.0 mg/kg/hr infusion and slightly higher during the
2.2 and 2.4 mg/kg/hr infusions.
Cardiac arrested and resuscitated rats
We observed decrease in mean arterial blood pressure
following cardiac arrest and cardiopulmonary resuscita-
tion as compared to the baseline, whereas heart rate and
blood temperature was similar (Table 2 and Figure 4C).
No differences in baseline conditions before cardiac
arrest and also the total time to ROSC and number
of shocks when comparing DHC treated animals pre-
treated with or without atropine (Table 2, p = ns).
Electrocardiography (ECG) and arterial blood pressure
tracings in resuscitated rats are shown in Figure 5. In all
the rats treated with DHC only, we observed several
short-lasting episodes of bradycardia associated with
hypotension. The episodes lasted from approximately
10 - 100 seconds and were observed about 5-10 times
during the entire course of the infusion of DHC, espe-
cially in the first hour. The ECG findings were
Figure 1 Mean arterial blood pressure (A) and heart rate (B), and aortic ejection time (C) in healthy conscious rats. Following baseline
characterization animals were infused at t = 0 with vehicle control for 1 hour followed by incremental doses of DHC of 1.0; 2.0; 2.2; 2.4; and 3.0
mg/kg/hr for 1 hour at each condition. Statistics: Each of the doses of DHC were compared to the vehicle control situation by a 1-way ANOVA
followed by Dunnett’s multiple comparison test ***p > 0.001, **p < 0.01, *p < 0.05. Values are expressed as average ± SE, with n = 6, see
Methods for further details.
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consistent with a third-degree AV block with no appar-
ent relationship between P waves and QRS complexes
(Figure 5A).
In animals treated with atropine prior to the infusion
of DHC the occurrence of a third-degree AV block
episodes and associated bradycardia and hypotension
was completely absent during the entire infusion period.
Also pre-treatment with atropine did not change the
effect of DHC on body temperature, heart rate and
mean arterial blood pressure (p = ns, Figure 4). Infusion
Figure 2 Curves of mean arterial blood pressure illustrating the episodes of hypotension and bradycardia occurring simultaneously
with motor events in Rat 1 (blue) and Rat 2 (red) during the infusion of DHC at (A) t = 360 minutes (i.e. following the end of the 3
mg/kg/hr dose) or (B) at t = 170 minutes (i.e. near the end of the 2 mg/kg/hr dose).
Figure 3 Blood temperature (A) and respiration rate (B) in healthy conscious rats. Following baseline characterization animals were infused
at t = 0 with vehicle control for 1 hour followed by incremental doses of DHC of 1.0; 2.0; 2.2; 2.4; and 3.0 mg/kg/hr for 1 hour at each condition.
Statistics: Each of the doses of DHC were compared to the vehicle control situation by a 1-way ANOVA followed by Dunnett’s multiple
comparison test ***p > 0.001, **p < 0.01, *p < 0.05. Values are expressed as average ± SE, with n = 6, see Methods for further details.
Fosgerau et al. BMC Cardiovascular Disorders 2010, 10:39
http://www.biomedcentral.com/1471-2261/10/39
Page 6 of 10
of DHC caused a decrease in blood temperature from
the 37°C at baseline reaching the minimum of 34°C at
the end of the 6 hour infusion (Figure 4A). Also, we
observed an initial increase in heart rate of approxi-
mately 10% within the first 2 hours of infusion (Figure
4B), which then declined towards the end of the infu-
sion back to baseline level. Finally, we observed a minor
increase in mean arterial blood pressure of approxi-
mately 20% (Figure 4C) during the infusion of DHC
compared to the baseline level of approximately
100 mmHg.
Discussion
On two occasions in the healthy rats we observed a
transient cardiovascular episode of bradycardia and
hypotension accompanied by a motor component during
the infusion of DHC, a TRPV1 agonist. Saito and Yama-
moto reported that oral administration of capsaicin to
rats caused tremor, clonic convulsion, dyspnea and lat-
eral or prone position before death, and speculated that
the cause of death may be associated to hypotension
[31]. In anaesthetized artificially ventilated dogs admi-
nistered intravenously with capsaicin elicited the Bezold-
Jarisch reflex [32], which is characterized by hypotension
and bradycardia [33]. Moreover, studies in TRPV1
receptor knock-out mice have emphasized the role of
the TRPV1 receptors in the activation of the Bezold-
Jarisch reflex [20]. Here we report transient episodes of
bradycardia and hypotension, which was accompanied
by convulsions/spasmodic movements. Also in pilot
dose finding experiments during infusion of very high
levels of DHC to healthy rats, we observed convulsions
or spasmodic movements followed by death in about
20% of the tested rats (data not shown). While we can-
not exclude that the origin of the cardiovascular collapse
observed might be ascribed to unidentified factors caus-
ing hypotension and bradycardia, collectively our obser-
vations are consistent with an activation of the Bezold-
Jarish reflex by stimulation of the TRPV1 receptor with
the agonist DHC.
This is the first study to characterize the cardiovascu-
lar profile of a TRPV1 agonist in a model of a compro-
mised cardiac system - the resuscitated rats. The results
indicate that the susceptibility of the resuscitated cardiac
arrest rats towards TRPV1 agonist induced Bezold-Jar-
isch reflex is increased compared to the healthy situa-
tion. The duration of the episodes of bradycardia/
hypotension was relatively short in the resuscitated rats
compared to the healthy rats. On the other hand 100%
Table 2 Baseline characteristics in rats resuscitated from
cardiac arrest
DHC only DHC + atropine
Bodyweight (g) 504 ± 8 504 ± 8
PaO2 (mmHg) 85 ± 4 81 ± 1
PaCO2 (mmHg) 39 ± 4 40 ± 4
pH 7.44 ± 0.02 7.45 ± 0.02
Blood temperature (°C) 37.0 ± 0.1 37.0 ± 0.1
Heart rate (beats/min) 333 ± 18 348 ± 8
Mean arterial blood pressure (mmHg) 145 ± 8 140 ± 4
ROSC attempts (n) 2.5 ± 1.2 2.0 ± 0.8
Shocks (n) 7 ± 4 7 ± 4
Total time to ROSC (min) 13.8 ± 1.0 13.3 ± 0.7
The table summarizes the baseline characteristics in rats prior to cardiac arrest
and resuscitation. Also the number of shocks and ROSC attempts and total
time to ROSC are given prior to the treatment with DHC and with or without
atropine. Statistics: We observed differences between the two study groups
on any of the measured parameters by comparison with a student’s t-test
(p = ns). Values are expressed as average ± SE, with n = 4 per group, see
Methods for further details.
Figure 4 Blood temperature (A), heart rate (B), and mean arterial blood pressure (C) in rats following a cardiac arrest and
cardiopulmonary resuscitation. Animals were treated with DHC (0.65 mg/kg/hr) and with atropine (5 mg/kg, red line) or without atropine
(green line) as pre-treatment. Statistics: We observed no effect of atropine on any of the measured parameters by comparison with a 2-way
ANOVA followed by Bonferroni post-test (p = ns). Values are expressed as average ± SE, with n = 4 per group, see Methods for further details.
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of the resuscitated rats compared to 33% of the healthy
rats displayed episodes of bradycardia/hypotension.
Also, the episodes occurred at lower levels of DHC in
the resuscitated cardiac arrest animals compared to the
healthy rats. The reason for this difference is not
known, but again may relate to the structural and func-
tional differences of the myocardium in the two models.
Cardiac arrest causes a decrease in myocardial contracti-
lity [34] and persistent cardiovascular derangements fol-
lowing CPR is seen including decreased cardiac output,
arrhythmias and morphological myocardial damage [35].
The ischemia and associated myocardial damage leads
to an increase of CO2 and lactic acid in the interstitial
compartment, which in turn cause cellular acidosis and
a decrease in pH [36]. Accordingly, buffer agents admi-
nistered during CPR may ameliorate post-resuscitation
myocardial dysfunction and thereby improve survival
[37]. Since the TRPV1 receptor is sensitized by extracel-
lular protons [38], the observed increased susceptibility
of the resuscitated rats versus the healthy rats towards
DHC-induced episodes of bradycardia and hypotension
therefore may be from a difference in the myocardial
pH in the two situations. However, we did not measure
myocardial pH in our experiment, and therefore we can-
not exclude that other factors such as the level of
anesthesia or the rate of infusion may have impacted on
the reported results.
Intravenous infusion of capsaicin caused a dose-
dependent increase in heart rate and blood pressure in
anaesthetized dogs [17]. Here, using DHC, we confirm
these results in healthy conscious rats and in resusci-
tated rats and show that arterial blood pressure and
heart rate increased by intravenous infusion. Similarly
we have observed tachycardia and hypertension in
response to intravenously infused DHC in conscious
calves (data not shown). This chronotropic effect of
DHC may be related to the release of GCRP following
activation of the TRPV1 receptor [26,27]. Using the
design of a step-wise incremental dose of DHC by
increasing the infusion rate we here demonstrate that
the general tachycardia/hypertension precedes the epi-
sodes of bradycardia/hypotension in the healthy rats.
Accordingly the episodes of bradycardia/hypotension,
which in turn may be mediated by the release of NKA
and SP (20, 27) may occur at higher level of TRPV1
activation: i.e., the biphasic or triphasic change of heart
Figure 5 Representative diagrams of the electrocardiography (ECG) data and arterial blood pressure data in rats following a cardiac
arrest, cardiopulmonary resuscitation and return of spontaneous circulation. (A) Third-degree AV block or complete heart block was as
seen in numerous occasions in rats treated with DHC only causing a marked bradycardia and hypotension. (B) Normal ECG as seen in animals
pre-treated with atropine.
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rate previously reported following administration of a
TRPV1 agonist [18,19] may be a result of pharmacoki-
netic properties.
In the healthy rats, the blood pressure changes during
the 2.0-mg/kg/hr infusion were not dose proportional.
During this infusion period, body temperature reached
its lowest level (approximately 4.5°C lower than vehicle
treatment). Because central control of blood pressure is
influenced by body temperature, the substantial decrease
in body temperature observed during the 2.0-mg/kg/hr
infusion may be responsible for the lack of dose propor-
tionality noted in the blood pressure changes. Ejection
time would normally be shorter in response to higher
heart rate and longer during lower heart rates. In this
experiment, heart rate was higher, but ejection time also
increased. This could be a predictor of a loss of cardiac
contractility.
Interestingly, the episodes of bradycardia and hypoten-
sion and third degree AV block elucidated by DHC in
the resuscitated situation could be fully prevented by
pre-treatment with the muscarinic acetylcholine recep-
tor antagonist atropine. It has been previously reported
that the cardiovascular effects of SP [23,25], but not of
NKA [18], could be prevented by atropine. Our data
emphasizes the role of the cholinergic nerves in the
mediation of the Bezold-Jarish reflex. It is not known
whether the observed cardiac effects were a result of a
direct stimulation of the vagus nerve, which do express
TRPV1 [14], or occurs indirectly with the vagus nerve
transmitting a signal generated via stimulation of
TRPV1 receptors in the CNS, and this may be subject
for further experimentation.
Conclusions
In conclusion, our results demonstrate that intrave-
nous infusion of the TRPV1 agonist DHC to healthy
rats causes an initial hypertension and tachycardia. At
high levels of DHC this may be followed by transient
episodes of bradycardia and hypertension, the so-called
Bezold-Jarisch reflex. We also demonstrate that the
resuscitated cardiac arrest situation has a higher sus-
ceptibility towards this reflex, which can be blocked by
pre-treatment with the muscarinic acetylcholine recep-
tor antagonist atropine. Clinically our results indicate
that while infusion of DHC may induce mild hypother-
mia relevant for the treatment of cardiac arrest
patients this may be accompanied by an increased
number of cardiac events and need of relevant pre-
treatment.
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